Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 20 versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 20 versus LESSINA 28.
AUROVELA 1/20 vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive